Literature DB >> 8619566

Fluconazole treatment of Candida albicans infection in mice: does in vitro susceptibility predict in vivo response?

J R Graybill1, L K Najvar, J D Holmberg, A Correa, M F Luther.   

Abstract

A series of fluconazole-susceptible and-fluconazole resistant Candida albicans fungal isolates were used to infect mice intravenously. Mice were treated with varying doses of fluconazole beginning one day after infection. For all of the 6 fluconazole-susceptible isolates, fluconazole was highly effective at <0.25 mg/kg of body weight twice daily. By contrast, fluconazole was less effective in at least 6 of 10 fluconazole-resistant isolates and was ineffective at > or = 40 mg/kg twice daily in 4 fluconazole-resistant isolates. Although the correlation is not precise, in vitro susceptibility testing of C. albicans can predict in vivo response to fluconazole.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8619566      PMCID: PMC162913          DOI: 10.1128/AAC.39.10.2197

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Mechanisms and clinical impact of antifungal drug resistance.

Authors:  H Vanden Bossche; D W Warnock; B Dupont; D Kerridge; S Sen Gupta; L Improvisi; P Marichal; F C Odds; F Provost; O Ronin
Journal:  J Med Vet Mycol       Date:  1994

2.  Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis.

Authors:  S Redding; J Smith; G Farinacci; M Rinaldi; A Fothergill; J Rhine-Chalberg; M Pfaller
Journal:  Clin Infect Dis       Date:  1994-02       Impact factor: 9.079

3.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.

Authors:  J L Goodman; D J Winston; R A Greenfield; P H Chandrasekar; B Fox; H Kaizer; R K Shadduck; T C Shea; P Stiff; D J Friedman
Journal:  N Engl J Med       Date:  1992-03-26       Impact factor: 91.245

Review 4.  Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.

Authors:  V J Fraser; M Jones; J Dunkel; S Storfer; G Medoff; W C Dunagan
Journal:  Clin Infect Dis       Date:  1992-09       Impact factor: 9.079

5.  Fluconazole resistance in Candida glabrata.

Authors:  C A Hitchcock; G W Pye; P F Troke; E M Johnson; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

6.  Molecular epidemiology of recurrent oral candidiasis in human immunodeficiency virus-positive patients: evidence for two patterns of recurrence.

Authors:  W G Powderly; K Robinson; E J Keath
Journal:  J Infect Dis       Date:  1993-08       Impact factor: 5.226

7.  Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial.

Authors:  D J Winston; P H Chandrasekar; H M Lazarus; J L Goodman; J L Silber; H Horowitz; R K Shadduck; C S Rosenfeld; W G Ho; M Z Islam; D N Buell
Journal:  Ann Intern Med       Date:  1993-04-01       Impact factor: 25.391

8.  A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

Authors:  J H Rex; J E Bennett; A M Sugar; P G Pappas; C M van der Horst; J E Edwards; R G Washburn; W M Scheld; A W Karchmer; A P Dine
Journal:  N Engl J Med       Date:  1994-11-17       Impact factor: 91.245

9.  Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1.

Authors:  M L Cameron; W A Schell; S Bruch; J A Bartlett; H A Waskin; J R Perfect
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

10.  Fluconazole-resistant Candida albicans.

Authors:  D J Boken; S Swindells; M G Rinaldi
Journal:  Clin Infect Dis       Date:  1993-12       Impact factor: 9.079

View more
  9 in total

1.  Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group.

Authors:  P Phillips; S Shafran; G Garber; C Rotstein; F Smaill; I Fong; I Salit; M Miller; K Williams; J M Conly; J Singer; S Ioannou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-05       Impact factor: 3.267

Review 2.  In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.

Authors:  David Andes
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

3.  Treatment of murine disseminated candidiasis with L-743,872.

Authors:  J R Graybill; L K Najvar; M F Luther; A W Fothergill
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model.

Authors:  A Valentin; R Le Guennec; E Rodriguez; J Reynes; M Mallie; J M Bastide
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

5.  The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans.

Authors:  Nathan P Wiederhold; Laura K Najvar; Annette W Fothergill; Dora I McCarthy; Rosie Bocanegra; Marcos Olivo; William R Kirkpatrick; Michael P Everson; Frederick P Duncanson; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

6.  Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasis.

Authors:  P Aviles; C Falcoz; R San Roman; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

7.  Sensitive bioassay for determination of fluconazole concentrations in plasma using a Candida albicans mutant hypersusceptible to azoles.

Authors:  O Marchetti; P A Majcherczyk; M P Glauser; J Bille; P Moreillon; D Sanglard
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 8.  Antifungal agents in the 1990s. Current status and future developments.

Authors:  C A Kauffman; P L Carver
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

9.  In vitro activity of the antifungal plant defensin RsAFP2 against Candida isolates and its in vivo efficacy in prophylactic murine models of candidiasis.

Authors:  Patricia M Tavares; Karin Thevissen; Bruno P A Cammue; Isabelle E J A François; Eliana Barreto-Bergter; Carlos P Taborda; Alexandre F Marques; Marcio L Rodrigues; Leonardo Nimrichter
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.